U.S. President Donald Trump is weighing whether to allow Nvidia to sell advanced artificial intelligence chips to China, Commerce Secretary Howard Lutnick told Bloomberg News in an interview on Monday.

LYFT, GTLB, EPAM, ONTO and SMTC lead a group of mid-cap tech stocks highlighted for strong demand trends and notable brokerage upside potential.

SAP expands partnerships with Bleu, Capgemini and Mistral AI to advance secure, sovereign cloud and AI innovation across Europe.

NEM's third-quarter gold output slid again as its Tier-1 pivot reshapes production and tests its 2025 outlook.

LULU leans on its surging digital ecosystem and AI-driven product reset as it works to balance global gains against U.S. softness and margin pressure.

Newmont and Agnico Eagle strengthen their positions with rising cash flows, project expansions, and steady dividends amid firm gold prices.

RACE's stock slump contrasts with resilient demand, rich margins and a deep order backlog that highlights the brand's long-term strength.

Novo Nordisk cuts self-pay prices for Wegovy and Ozempic in the United States, aiming to expand access and counter falling demand.

Red Cat has sharply declined to $6 despite strong momentum in the U.S. drone market and new product launches. The drone manufacturer reported record Q3 revenue with growth of 646% YoY, but 2025 guidance was cut significantly due to government contract delays. The company is expanding into uncrewed surface vessels, targeting a $150 million opportunity, and maintains a robust $213 million cash balance.

Alphabet (GOOGL) is now the third biggest company in the SPX behind Nvidia (NVDA) and Apple (AAPL) after shares surged on a company deal with NATO. Tom White takes traders through the options front with neutral to bullish example trades following the headlines pushing shares higher.

MONSEY, N.Y., Nov. 24, 2025 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Exact Sciences Corporation (Nasdaq: EXAS) (“Exact Sciences”) to Abbott Laboratories for $105.00 per share in cash.

Kimberly-Clark, an American multinational consumer goods and personal care corporation, is now a $34 billion (by market cap) consumer products leader. On November 3, Kimberly-Clark announced a $48.7 billion deal to acquire Kenvue Inc. KMB increased its dividend for 53 consecutive years, with a 10-year dividend growth rate of 4%.

ATHENS, Greece, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Icon Energy Corp. (“Icon” or the “Company”) (Nasdaq: ICON), an international shipping company providing worldwide seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels, announced today that to date it has sold 132,144 shares of the Company's common shares pursuant to advances under the Standby Equity Purchase Agreement (“SEPA”) at an average price per share of $1.86.

Editor's note: Any and all references to time frames longer than one trading day are for purposes of market context only, and not recommendations of any holding time frame. Daily rebalancing ETFs are not meant to be held unmonitored for long periods.

The ALPS Electrification Infrastructure ETF (ELFY) is drawing investor attention as U.S. electricity demand heads for its fastest growth in decades, driven by artificial intelligence data centers, manufacturing reshoring, and expanding electric vehicle infrastructure. The fund has pulled in $79.9 million over the past six months and $37.

Dominion Energy sharpens its 2025 outlook with rising estimates and a massive investment plan to expand clean-energy capacity.

United States Antimony bets on high-grade Montana and Alaska ore to replace costly imports and target a major lift in gross margins.

Intuitive Surgical's robotics surge and Medtronic's broad innovation push set the stage for a high-tech showdown in next-gen minimally invasive care.

The gig economy offers numerous advantages, and for investors aiming to benefit from this expanding trend, it may be wise to monitor stocks like AMZN, DASH and LYFT.

Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.